Continuous Renal Replacement Therapy (CRRT) Consumables Market Size, Share & Industry Analysis, By Type (Dialysates, Replacement Solutions, Filters, Catheters, and Others), By Modality (Slow Continuous Ultra Filtration (SCUF), Continuous Venovenous Hemofiltration (CVVH), Continuous Venovenous Hemodialysis (CVVHD), and Continuous Venovenous Hemodiafiltration (CVVHDF)), and Regional Forecast, 2025-2032

The global continuous renal replacement therapy (CRRT) consumables market size was valued at USD 847.0 million in 2024. The market is projected to grow from USD 912.6 million in 2025 to USD 1,581.5 million by 2032, exhibiting a CAGR of 8.2% during the forecast period. North America dominated the continuous renal replacement therapy (CRRT) consumables market with a market share of 38.21% in 2024.

Continuous renal replacement therapy (CRRT) consumables are medical products used during CRRT procedures to support kidney function in patients suffering from kidney diseases or acute kidney injury. These consumables include a range of products such as dialysate, filters, anticoagulants, and replacement fluids.

The global growth of the market is attributed to the growing prevalence of chronic kidney disease, rising preference for continuous renal replacement therapies over traditional dialysis, and technological advancements in CRRT. Moreover, active government involvement to promote superior renal care along with better convenience and treatment outcomes is also expected to positively impact the market for continuous renal replacement therapy, and hence the CRRT consumables.

Some of the major players in the market are Medtronic, Baxter, Fresenius Medical Care, Nipro, and Asahi Kasei. These players emphasize offering cutting-edge services, new product launches, and strategic partnerships, enabling them to maintain substantial market share. In addition, an established market presence coupled with a strong distribution network is also expected to offer a favorable environment for such market players to generate lucrative revenues.

MARKET DYNAMICS

Market Drivers

Increasing Incidence of Acute Kidney Injury to Boost CRRT Adoption

Substantial growth in acute kidney injury (AKI) is one of the prominent factors driving the demand for CRRT consumables. A significant number of AKI cases require a greater number of continuous renal replacement treatments, which subsequently leads to higher demand for CRRT systems and disposables.

• For instance, according to the data published by the Journal of Nephrology in September 2023, an estimated 13.3 million people suffer from acute kidney injury per year across the globe. The study also highlights that lower and middle-income countries are highly susceptible to acute kidney injury.

In order to manage critical-level acute kidney injury, it is important to provide comprehensive treatment to the patient. Such a high prevalence rate offers a lucrative environment for increased adoption of continuous renal replacement therapies. In addition, a growing number of product launches are further expected to boost demand for its adoption and respective consumables.

• For instance, in March 2023, Quanta Dialysis Technologies received FDA approval for its Quanta Dialysis System, which features two distinct modes of continuous renal replacement therapy: continuous venovenous hemodialysis (CVVHD) and slow continuous ultrafiltration (SCUF).

Market Restraints

Requirement of Specialized Infrastructure for CRRT Coupled with High Cost of CRRT to Restrict Product Adoptions

Though the CRRT offers better treatment outcomes compared to traditional dialysis, the therapy is complex in itself. The treatment requires highly trained personnel to manage complicated protocols, monitor patients continuously, and handle potential difficulties such as catheter-related infections or electrolyte imbalances. Many developing regions lack sufficiently skilled ICU staff, which impedes the broader use of CRRT consumables in routine practice.

• For instance, according to a study published in Kidney International Reports in June 2025, except for four states in India, the CRRT services were highly unavailable in India. Certain factors, such as a lack of expertise, the cost of CRRT machines, and inadequate healthcare vision amongst policymakers, were responsible for this infrastructure crisis in the country.
• Moreover, according to the same study, one session of CRRT in India costs around USD 500 - 800.

The cost burden of CRRT procedures is significant. Consumables such as hemofilters, bloodline sets, dialysates, fluids, and accessory items accumulate high recurring costs, subsequently lowering the adoption of CRRT procedures.

Market Opportunities

Increasing Emphasis on Providing Value-Based Renal Care in Intensive Care Units Globally Boosts Market Growth

Recently, healthcare providers have been extensively focusing on providing integrated, value-based care, especially in intensive care units. As hospitals continue to focus on improving patient outcomes and reducing ICU stay durations, demand for high-performance, easy-to-use CRRT consumables has surged. This creates a significant opportunity for companies to introduce next-generation filters, cartridges, and fluid sets that reduce therapy interruptions and optimize toxin removal efficiency.

In addition, market players are also focusing on the development and deployment of technologically advanced solutions for a better experience and care. These innovations are estimated to contribute to the adoption of value-based care models within healthcare facilities.

• For instance, in March 2024, Fresenius Medical Care announced the launch of its new Augmented Reality (AR) application aimed at simplifying training for healthcare professionals in kidney replacement therapy in intensive care units.

Market Challenges

Absence of Standardized Treatment Protocols to Deter Market Growth

The lack of standardized clinical protocols presents a substantial challenge for the continuous renal replacement therapy (CRRT) consumables market growth. Unlike conventional dialysis, CRRT settings differ from institution to clinician, including dosing, modality, and fluid composition. This inconsistency makes it difficult for manufacturers to design universal consumables that meet diverse clinical preferences while ensuring compatibility with various machines.

Furthermore, the absence of globally accepted best practices delays the adoption of CRRT and innovative consumables, as clinicians are cautious about switching to new products without clear guidelines. This inconsistency in usage protocols hampers product standardization and makes clinical trials and outcome tracking more complex, slowing regulatory approvals and evidence-based marketing, hindering market growth.

CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT) CONSUMABLES MARKET TRENDS

Technological Advancements and Digital Integration to Support Increased Adoption of CRRT

The continuous renal replacement therapy market is witnessing growing integration of digital health technologies and automation into renal care workflows due to exhaustive developments in software technologies. Manufacturers are increasingly developing smart consumables that are embedded with tracking features, enabling real-time monitoring of usage, expiration, and therapy parameters.

• For instance, in July 2019, Baxter International announced the approval and launch of its PrisMax system and integrated TherMax blood warmer, designed to offer therapeutic plasma exchange and continuous renal replacement therapy (CRRT). The new technology is specially designed to simplify therapy delivery.

Additionally, strategic partnerships between hospitals and manufacturers, centered around bulk procurement and subscription-based supply of consumables, are emerging as a strategic cost-control model. These evolving dynamics reflect a broader movement toward smarter, safer, and more sustainable CRRT therapies, making consumables a focus area for competitive differentiation and product innovation.

Download Free sample to learn more about this report.

Impact of COVID-19

The COVID-19 pandemic had a negative impact on the market in 2020, primarily due to the decline in renal replacement procedures and the maximum focus of healthcare authorities on the management of the pandemic.

• For instance, according to the article published by the National Center for Biotechnology Information (NCBI) in March 2022, there was an estimated 21% decline in the total number of dialysis procedures during the study.

Though during the pandemic period, there was a significant decline in the number of dialysis procedures, the market gradually recovered to pre-pandemic levels in 2021 and 2022 due to the relaxation of lockdown restrictions and an extensive rise in the number of renal replacement therapies.

SEGMENTATION ANALYSIS

By Type

Increasing Number of CRRT Procedures Boosts the Replacement Solution Segment’s Growth

By type, the market is divided into dialysates, replacement solutions, filters, catheters, and others.

The replacement solutions segment dominates the continuous renal replacement therapy (CRRT) consumables market in terms of both market share and CAGR. The segment includes products involved in maintaining fluid and electrolyte balance during continuous renal replacement therapy. The strong demand for replacement solutions is driven by the increasing prevalence of sepsis-related AKI and multi-organ failure in intensive care units. Moreover, a higher number of procedures is expected to further boost the adoption of replacement solutions.

The dialysate segment is expected to register the second-fastest CAGR during 2025-2032. Factors contributing to this growth include the growing adoption of continuous dialysis methods across developed and developing healthcare systems, a focus on a patient-centric approach, and advancements in electrolyte-balanced dialysate formulations.

By Modality

Superior Operational Efficiency Boosted Continuous Venovenous Hemodiafiltration (CVVHDF) Segment Growth

By modality, the market is divided into low Continuous Ultra Filtration (SCUF), Continuous Venovenous Hemofiltration (CVVH), Continuous Venovenous Hemodialysis (CVVHD), and Continuous Venovenous Hemodiafiltration (CVVHDF).

In terms of mode, continuous veno-venous hemodiafiltration accounted for the highest market share and CAGR in the continuous renal replacement therapy (CRRT) consumables market. CVVHDF is widely adopted due to its ability to combine the benefits of both diffusion and convection mechanisms, enabling comprehensive solute clearance across a wide range of molecular weights. This mode is often selected for critically ill patients with multiple metabolic complications, as it offers enhanced control over acid-base balance, uremia, and fluid overload.

CVVH (Continuous Veno-Venous Hemofiltration) is the second-leading modality in the market. Its growth is supported by clinical preference for convection-based therapies, especially in cases involving high levels of inflammatory mediators and larger solutes. CVVH is widely adopted for its efficacy in handling cases where diffusion alone cannot adequately address fluid overload and solute clearance.

CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT) CONSUMABLES MARKET REGIONAL OUTLOOK

By geography, the market is categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America

To get more information on the regional analysis of this market, Download Free sample

North America dominated the global market in 2024, with the regional value at USD 323.6 million in 2024. Certain factors, such as awareness about CRRT, adequate availability of dialysis centers, and robust healthcare infrastructure, are estimated to drive the continuous renal replacement therapy (CRRT) consumables market growth.

In the U.S., emphasis on superior quality of patient care coupled with the increasing prevalence of acute kidney injury is likely to have a positive impact on market growth. In addition, the government’s active participation in encouraging renal care programs is also driving the market growth.

• For instance, in February 2025, U.S. Renal Care announced the launch of its new employee benefit program, intending to support frontline team members to become nephrology nurses. These resources will be trained to conduct renal procedures, including CRRT. Such strategic steps will help the healthcare authorities to bridge the gap between demand and the availability of infrastructure.

Europe

The market in Europe held a substantial share in 2024. The region’s strong research and development activities, coupled with an aging population and probable growth in renal care requirements, is expected to support the growth of the CRRT consumables in the region.

• For instance, in November 2018, the German Research Foundation approved funding of USD 12.08 million for kidney disease prevention research. The research focuses on developing new therapies that will prevent kidney injuries.

Asia Pacific

Asia Pacific is expected to witness the highest CAGR during the forecast period. The growth is attributed to the increasing aging population in the region, which may increase the susceptibility to kidney and renal conditions, driving the demand for CRRT in the region.

• For instance, according to the data published by the State Council of the People’s Republic of China, in October 2024, China's population aged 60 years and above reached around 297.0 million in 2023. This substantial population is prone to nephrological conditions, offering a considerable opportunity for market growth.

Latin America and Middle East & Africa

The growth of the Latin America market is attributed to increasing investments in renal care and active government involvement aimed at offering better patient care. On the other hand, the Middle East and Africa are expected to witness stagnant growth during the forecast period. The growth is mainly attributable to the growing number of dialysis centers, extensive developments for commencing cutting-edge ICUs, and increasing awareness about the benefits offered by continuous renal replacement therapy procedures.

• For instance, in March 2025, SAHA and PureHealth entered into a strategic partnership to open a dialysis center in Abu Dhabi. The new center is expected to cater to the demand for critical kidney care in the region.

COMPETITIVE LANDSCAPE

Key Industry Players

Market Players Emphasis on Strategic Partnerships and Introduction of Advanced Products to Boost their Market Share

The market is consolidated, with major players such as Medtronic, Baxter, and Fresenius Medical Care holding a significant portion of the global continuous renal replacement therapy (CRRT) consumables market share in 2024. Their market dominance is attributed to their extensive global reach and a wide range of advanced product offerings. These companies are continuously introducing new solutions for renal care .

Moreover, other prominent companies such as Nipro, B. Braun SE, and Asahi Kasei Medical Co., Ltd. are actively involved in strategic initiatives such as mergers, acquisitions, partnerships, and collaborations to increase their market share and enhance competitiveness.

LIST OF KEY CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT) CONSUMABLES MARKET COMPANIES PROFILED:

• Baxter (U.S.)
• B Braun SE (Germany)
• Fresenius Medical Care AG & Co. KGaA (Germany)
• Asahi Kasei Medical Co., Ltd. (Asahi Kasei Corporation) (Japan)
• NIPRO (Japan)
• TORAY MEDICAL CO, LTD. (TORAY INDUSTRIES, INC.) (Japan)
• Nikkiso Co., Ltd. (Japan)
• Medtronic (Ireland)

KEY INDUSTRY DEVELOPMENTS

• July 2024: A group of researchers at UCLA announced the development of a new machine learning model capable of predicting survival analysis of patients on continuous renal replacement therapy.
• May 2024: Invizius announced an update on its trial for H-Guard, which can be utilized during CRRT. The company is conducting this activity in collaboration with TCRSolutions.
• May 2022: Baxter received FDA approval for its ST set used in continuous renal replacement therapy (CRRT). The newly introduced set is a disposable, pre-connected, extracorporeal circuit that is utilized for blood purification.
• May 2020: HHS, in collaboration with Fresenius Medical Care, provided dialysis machines to healthcare facilities intending to cater to the demand for dialysis during the pandemic.
• August 2019: Baxter Canada announced the launch of its PrisMax system and integrated TherMax blood warmer, which is specifically used for continuous renal replacement therapy (CRRT).

REPORT COVERAGE

The global continuous renal replacement therapy (CRRT) consumables market analysis provides market size and forecast by type and modality segments. It covers market dynamics and emerging market trends. It offers insights into the prevalence of key conditions, the number of surgeries, new product launches, and key industry developments. The report provides an in-depth analysis of the competitive landscape, including insights into market share distribution and detailed profiles of leading companies.

To gain extensive insights into the market, Download for Customization

Report Scope & Segmentation